Disc Medicine Attracts Major Biotech Investor Bet, Even as Stock Faces Near-Term Volatility

Hedge fund BVF recently signaled strong conviction in Disc Medicine by establishing a substantial $51.62 million position in the clinical-stage biotech company during the fourth quarter. The investment—acquiring 650,000 shares—arrived at an intriguing moment: shortly before the FDA’s Complete Response Letter and the subsequent 20% single-day decline that followed in February 2026.

The timing raises an important question for investors: what makes a sophisticated hedge fund willing to build exposure to a biotech company right before a regulatory setback?

Biotech Hedge Fund’s Strategic Conviction in Disc Medicine

The scale of BVF’s new position in Disc Medicine, now representing 1.74% of the fund’s 13F reportable assets under management, reflects meaningful capital deployment. At the time of the February 17, 2026 SEC filing, Disc Medicine shares were priced at $65.57, up 20% over the prior year despite the recent turbulence.

BVF’s portfolio context matters here. The fund maintains concentrated exposure to differentiated biotech platforms, with top holdings including Kymera Therapeutics ($428.2 million, 14.4% of AUM), Revolution Medicines ($267.4 million, 9.0%), MoonLake Therapeutics ($260.3 million, 8.8%), and others. This Disc Medicine position fits a familiar playbook: targeted investment in companies with clear binary catalysts and compelling science-backed theses.

FDA Decision Didn’t Derail the Investment Thesis

The FDA’s Complete Response Letter, issued in February, acknowledged that bitopertin successfully lowered PPIX levels in EPP (Erythropoietic Protoporphyria) patients. However, the agency determined existing data lacked sufficient clinical outcome correlation, effectively pausing near-term commercialization hopes.

Yet this regulatory hurdle appears to be exactly what BVF anticipated—or at minimum, accepted as part of the biotech risk profile. The investment was likely constructed on the underlying science and balance sheet durability rather than near-term approval expectations. The FDA explicitly pointed to the ongoing Phase 3 APOLLO trial as the path forward, with topline data expected in Q4 2026. If those results prove supportive, management guides a potential updated FDA decision by mid-2027.

Disc Medicine’s Financial Runway Underpins the Wager

A critical detail often overlooked: Disc Medicine ended 2025 with approximately $791 million in cash and marketable securities. The company guides its cash runway into 2029, providing a multi-year window to advance the APOLLO trial and potentially secure approval.

This capital durability is central to understanding BVF’s conviction. In biotech investing, binary outcomes are inevitable—approval or rejection, validation or disappointment. But companies with extended runways can absorb regulatory delays and setbacks without existential crises. Disc Medicine’s balance sheet suggests the company can execute its strategy despite delayed near-term catalysts.

The Broader Biotech Thesis: Long Innovation, Short Volatility Tolerance

Disc Medicine represents a deeper investing thesis about clinical-stage biotechnology. The company operates in red blood cell biology, developing novel therapeutics for serious hematologic diseases—a differentiated platform within a crowded biotech landscape. The focus on fundamental biological pathways and targeted drug development offers competitive positioning.

For investors considering whether to follow BVF into this position, the calculus is straightforward: you’re betting on APOLLO trial success, regulatory approval in 2027, and a rare disease market large enough to justify a multi-billion dollar valuation. That’s inherently volatile and uncertain.

The Investment Decision: Science, Balance Sheet, and Patience

Ultimately, the Disc Medicine thesis is no longer about near-term momentum. It hinges entirely on APOLLO data and the company’s ability to navigate the extended regulatory timeline with its current cash position intact.

BVF’s $52 million bet appears to reflect confidence in both the underlying science and management’s execution capability. Whether that conviction proves justified will depend on Phase 3 trial results expected later this year and the FDA’s subsequent decision. For investors weighing exposure to Disc Medicine, understanding the binary nature of biotech investing and your own risk tolerance for extended development timelines is essential before committing capital.